Looks like you clickedhttps://multiplesclerosisnewstoday.com/2018/08/30/tecfidera-gilenya-equally-effective-but-more-ms-patients-stop-tecfidera-study/?utm_source=Multiple+Sclerosis&utm_campaign=701fb06bfa-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-701fb06bfa-72136581
If you do not want to visit that page, you can close this browser tab.
